Respiratory syncytial virus ... to complex techniques performed in a laboratory (cell culture, nucleic acid amplification and immunofluorescence assays); however, rapid antigen-detection tests ...

The microbiologic confirmation of RSV infection is based on detecting the virus in a sample of wash or a swab obtained from the nasopharyngeal cavity. A variety of laboratory techniques can be ...

In August 2023, BD received FDA clearance for its BD Respiratory Viral Panel (RVP) for the BD MAXTM System. This innovative single molecular diagnostic combination test swiftly identified and ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

On Tuesday, the FDA approved Pfizer Inc’s (NYSE:PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, to prevent lower respiratory tract ...

Coughing, sneezing, and high temperature are common signs of a cold. While these may look harmless, they can also be symptoms ...

Our primary goal was to develop two real-time multiplex polymerase chain reaction (PCR) assays for simultaneous detection of ...

has been approved for the prevention of lower respiratory tract diseases, such as pneumonia and bronchitis, caused by respiratory syncytial virus, or RSV, in people between the ages of 18 and 59.

Respiratory syncytial virus and influenza activity are on the rise in parts of the country, particularly among young children, according to the CDC's latest respiratory virus updates. Overall, the ...